Osimertinib (Tagrisso) for locally advanced or metastatic non-small cell lung cancer, EGFR mutation positive (Ex19del or L858R) – first line

Osimertinib is a drug that prevents, inhibits or halts the development of a tumour. It is administered as a tablet. If licensed, osimertinib could offer an additional treatment option for patients with advanced NSCLC that is EGFR mutation positive (Ex19del or L858R) in the first line setting.